Charles River Laboratories Launches Innovative Plasmid Offering to Enhance Gene Therapy Manufacturing Efficiency in Collaboration with Genetic Cures for Kids
WILMINGTON, Mass. - Charles River Laboratories International, Inc. (NYSE: CRL), a leading contract development and manufacturing organization (CDMO), has announced the introduction of their new off-the-shelf Rep/Cap plasmid offering. This innovative product is specifically designed to streamline adeno-associated virus (AAV)-based gene therapy programs, furthering the company’s commitment to advancing the field of genetic medicine.
The Rep/Cap plasmid offering complements Charles River’s existing lentiviral packaging and AAV Helper plasmid products, providing a comprehensive range of solutions for gene therapy manufacturing. By offering a ready-to-use solution, this new product eliminates the need for time-consuming and complex plasmid development, significantly expediting the manufacturing process. This efficiency will ultimately contribute to faster gene therapy development and improved patient access to life-saving treatments.
A key factor in this advancement is Charles River’s collaboration with Genetic Cures for Kids Inc (GC4K), an Australian non-profit foundation dedicated to finding rare disease cures through research programs and clinical trials. Through a plasmid DNA contract development and manufacturing organization (CDMO) collaboration, Charles River and GC4K are jointly driving innovation in gene therapy production. This collaboration will not only enhance the capabilities of both organizations but also accelerate the availability and affordability of gene therapies for rare diseases.
Founded in 2021 by parents Golden and Chris Whitrod, GC4K’s mission, known as Our Moons Mission, centers around finding cures for rare diseases. This collaboration with Charles River aligns with their vision and allows them to leverage the CDMO’s expertise and resources to advance gene therapy development and manufacturing.
In addition to their innovative plasmid offering, Charles River has expanded its CliniPrime suite of Good Manufacturing Practice (GMP)-compliant products with the introduction of CliniPrime Cryopreserved Leukopaks. These products, designed for cell therapy development and manufacturing, meet regulatory guidelines for clinical trial development and commercial production of advanced therapies. This expansion further solidifies Charles River’s position as a leader in supporting the advancement of gene-modified cell therapies.
As the field of gene therapy continues to flourish and transform the landscape of medicine, Charles River’s commitment to innovation and collaboration with organizations like GC4K will play a crucial role in accelerating the development and manufacturing of life-changing therapies. With their comprehensive range of genetic medicine solutions, Charles River is well-positioned to help meet the increasing demand for safe, effective, and accessible gene therapies for rare diseases.
Comments